Recommendation of the President – Imjudo (tremelimumab) + Imfinzi (durvalumab)

On 1 October 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 106/2024 on the evaluation of the drug combination Imjudo (tremelimumab) + Imfinzi (durvalumab) under the drug program “Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)”

Publication in Public Information Bulletin (BIP) >>